OncoMatch/Clinical Trials/NCT06218810
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Is NCT06218810 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cadonilimab + bevacizumab + FOLFOX for metastatic colorectal cancer.
Treatment: Cadonilimab + bevacizumab + FOLFOX — The dual immunotherapy regimen significantly outperformed previous chemotherapy or immunomonotherapy for MSS type advanced CRC in two key efficacy indicators, ORR and PFS. Researchers have also conducted in-depth analysis of patient transcriptomics, immune microenvironment characteristics, and other related information, which is expected to guide more accurate immune combination therapy for CRC in the future. Our team plans to conduct a multicenter, prospective, single arm clinical trial in patients with RAS mutant MSS unresectable metastatic colorectal cancer, with a focus on observing the 1-year progression free survival rate of the combination of two chemotherapy drugs, bevacizumab and Cadonilimab, as well as ORR, perioperative safety, and long-term survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: RAS mutation
RAS mutation
Required: MMR proficient
pMMR
Required: MSI microsatellite stable
MSS
Excluded: RAS wild-type
Participants of RAS wild-type [excluded]
Excluded: MMR deficient
dMMR [excluded]
Excluded: MSI microsatellite instability-high
MSI-H [excluded]
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systematic anti-tumor therapy
Colorectal cancer patients who have not received systematic anti-tumor therapy in the past
Cannot have received: systematic anti-tumor therapy (chemotherapy)
Exception: within 3 weeks prior to the first administration
Received systematic anti-tumor therapy (chemotherapy) within 3 weeks prior to the first administration
Cannot have received: immunotherapy against tumors
Have received any immunotherapy against tumors in the past, including immune checkpoint inhibitors (such as anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.), immune checkpoint agonists (such as ICOS, CD40, CD137, GITR, OX40 antibodies, etc.), immune cell therapy, and any treatment targeting the immune mechanism of tumors
Cannot have received: non-specific immunomodulatory therapy (interleukin, interferon, thymosin)
Exception: excluding IL-11 used to treat thrombocytopenia; within 2 weeks before the first administration
Received non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc., excluding IL-11 used to treat thrombocytopenia) within 2 weeks before the first administration
Cannot have received: Chinese herbal medicine or traditional Chinese patent medicines and simple preparations with anti-tumor indications
Exception: within 1 week before the first administration
Chinese herbal medicine or traditional Chinese patent medicines and simple preparations with anti-tumor indications was received within 1 week before the first administration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify